Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review

June 2021 | 26 pages | ID: I8819B9032DEN
GlobalData

Abstracts

Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer, and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH Key Recent Developments

Mar 30,2021: Immatics Announces Full Year 2020 Financial Results and Corporate Update
Jun 04,2020: Immatics appoints Cedrik Britten as chief medical officer
Feb 21,2020: GSK and Immatics partner on cell therapies for cancer

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Immatics Biotechnologies GmbH - Key Facts
Immatics Biotechnologies GmbH - Key Employees
Immatics Biotechnologies GmbH - Key Employee Biographies
Immatics Biotechnologies GmbH - Major Products and Services
Immatics Biotechnologies GmbH - History
Immatics Biotechnologies GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Immatics Biotechnologies GmbH - Business Description
Immatics Biotechnologies GmbH - SWOT Analysis
SWOT Analysis - Overview
Immatics Biotechnologies GmbH - Strengths
Immatics Biotechnologies GmbH - Weaknesses
Immatics Biotechnologies GmbH - Opportunities
Immatics Biotechnologies GmbH - Threats
Immatics Biotechnologies GmbH - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Immatics Biotechnologies GmbH, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Mar 30, 2021: Immatics Announces Full Year 2020 Financial Results and Corporate Update
Jun 04, 2020: Immatics appoints Cedrik Britten as chief medical officer
Feb 21, 2020: GSK and Immatics partner on cell therapies for cancer

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Immatics Biotechnologies GmbH, Key Facts
Immatics Biotechnologies GmbH, Key Employees
Immatics Biotechnologies GmbH, Key Employee Biographies
Immatics Biotechnologies GmbH, Major Products and Services
Immatics Biotechnologies GmbH, History
Immatics Biotechnologies GmbH, Other Locations
Immatics Biotechnologies GmbH, Key Competitors
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Immatics Biotechnologies GmbH, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021